Avandia topped the list with 1,354 deaths reported to the FDA in 2009. The drug, also known by its generic name rosiglitazone, has been the focus on scientific controversy over the possible health risks and Glaxo faces numerous lawsuits. Studies have shown Avandia increases risk of heart failure and other cardiovascular problems such as heart attacks and strokes. Glaxo has defended the way it handled the heart risk of Avandia.

GSK’s Avandia tops list of deadly drugs in 2009

Josh Goldstein

Posted:
Thursday, June 17, 2010, 1:06 PM

The GlaxoSmithKline diabetes drug Avandia topped list of drugs linked to fatal adverse events in 2009, according to an analysis of U.S. Food and Drug Administration records by Horsham, Pa.-based Institute for Safe Medication Practices.